Davy Vancampfort1, Simon Rosenbaum, Philip B Ward, Zachary Steel, Oscar Lederman, Alice Veronica Lamwaka, Justin W Richards, Brendon Stubbs. 1. From KU Leuven Department of Rehabilitation Sciences (Vancampfort) and the University Psychiatric Centre, Leuven-Kortenberg, Belgium (Vancampfort); School of Psychiatry (Rosenbaum, Ward, Steel, Lederman), University of New South Wales, Sydney, NSW, Australia; Department of Pharmacy, Faculty of Medicine (Lamwaka), Gulu University, Uganda; School of Public Health & Charles Perkins Centre (Richards), University of Sydney, Sydney, NSW, Australia; Physiotherapy Department (Stubbs), South London and Maudsley NHS Foundation Trust, London, United Kingdom; and Health Service and Population Research Department (Stubbs), Institute of Psychiatry, King's College London, London, United Kingdom.
Abstract
OBJECTIVE: To clarify the prevalence and predictors of Type 2 diabetes mellitus (T2DM) in people with posttraumatic stress disorder (PTSD) and where possible compare this to healthy controls. METHODS: We searched major electronic databases until May 2015 for studies reporting T2DM prevalence in people with PTSD. Two independent authors extracted data and completed methodological quality appraisal. A random-effects meta-analysis was used. RESULTS: From 1171 candidate publications after exclusions, nine publications were included (n = 23,396; 28.6% male; mean age = 35-60 years). The overall prevalence of T2DM was 10.0% (95% confidence interval [CI] = 8.1%-12.0%). Subgroup analysis demonstrated that war veterans experience higher prevalence of T2DM (16.3%; 95% CI = 5.2%-31.8%; n studies = 3, n = 473) compared with mixed samples (11.8%; 95% CI = 6.34-18.7, p < .001; n studies = 4, n = 2753). Increasing age (β = 0.0593, 95% CI = 0.010-0.109, z = 2.34, p = .019), median year of publication (β = -0.08, 95% CI = -0.14 to -0.03, z = -3.09, p = .002), and a lower percentage of white participants (β = -3.21, 95% CI = -5.12 to -1.29, z = -2.28, p = .001) predicted prevalence of T2DM. A relative risk meta-analysis comparing controls (n = 125,723) against those with PTSD (n = 23,203) demonstrated a significantly increased risk of T2DM (n studies = 5, relative risk = 1.49, 95% CI = 1.17-1.89, p = .001). CONCLUSIONS: People with PTSD are at a high risk for developing T2DM. The current findings should, however, be interpreted with caution because most studies were based on self-report data.
OBJECTIVE: To clarify the prevalence and predictors of Type 2 diabetes mellitus (T2DM) in people with posttraumatic stress disorder (PTSD) and where possible compare this to healthy controls. METHODS: We searched major electronic databases until May 2015 for studies reporting T2DM prevalence in people with PTSD. Two independent authors extracted data and completed methodological quality appraisal. A random-effects meta-analysis was used. RESULTS: From 1171 candidate publications after exclusions, nine publications were included (n = 23,396; 28.6% male; mean age = 35-60 years). The overall prevalence of T2DM was 10.0% (95% confidence interval [CI] = 8.1%-12.0%). Subgroup analysis demonstrated that war veterans experience higher prevalence of T2DM (16.3%; 95% CI = 5.2%-31.8%; n studies = 3, n = 473) compared with mixed samples (11.8%; 95% CI = 6.34-18.7, p < .001; n studies = 4, n = 2753). Increasing age (β = 0.0593, 95% CI = 0.010-0.109, z = 2.34, p = .019), median year of publication (β = -0.08, 95% CI = -0.14 to -0.03, z = -3.09, p = .002), and a lower percentage of white participants (β = -3.21, 95% CI = -5.12 to -1.29, z = -2.28, p = .001) predicted prevalence of T2DM. A relative risk meta-analysis comparing controls (n = 125,723) against those with PTSD (n = 23,203) demonstrated a significantly increased risk of T2DM (n studies = 5, relative risk = 1.49, 95% CI = 1.17-1.89, p = .001). CONCLUSIONS:People with PTSD are at a high risk for developing T2DM. The current findings should, however, be interpreted with caution because most studies were based on self-report data.
Authors: Carmen Vidal; Ruth Polo; Kiara Alvarez; Irene Falgas-Bague; Ye Wang; Benjamin Lê Cook; Margarita Alegría Journal: Psychosom Med Date: 2018-09 Impact factor: 4.312
Authors: Ashley Winning; Paola Gilsanz; Karestan C Koenen; Andrea L Roberts; Qixuan Chen; Jennifer A Sumner; Eric B Rimm; M Maria Glymour; Laura D Kubzansky Journal: Am J Prev Med Date: 2017-03-18 Impact factor: 5.043
Authors: Jessica L McCurley; Angela P Gutierrez; Julia I Bravin; Neil Schneiderman; Samantha A Reina; Tasneem Khambaty; Sheila F Castañeda; Sylvia Smoller; Martha L Daviglus; Matthew J O'Brien; Mercedes R Carnethon; Carmen R Isasi; Krista M Perreira; Greg A Talavera; Mingan Yang; Linda C Gallo Journal: Ann Behav Med Date: 2019-10-07
Authors: Nanna Lindekilde; Stine H Scheuer; Femke Rutters; Lenette Knudsen; Mathias Lasgaard; Katrine H Rubin; Jan Erik Henriksen; Mika Kivimäki; Gregers S Andersen; Frans Pouwer Journal: Diabetologia Date: 2021-11-29 Impact factor: 10.122
Authors: Lisa Scarton; Luciana E Hebert; R Turner Goins; Jason G Umans; Luohua Jiang; Ashley Comiford; Sixia Chen; Ashley White; Tara Ritter; Spero M Manson Journal: Qual Life Res Date: 2021-04-10 Impact factor: 4.147
Authors: Farrukh M Koraishy; Steven G Coca; Beth E Cohen; Jeffery F Scherrer; Frank Mann; Pei-Fen Kuan; Benjamin J Luft; Sean A P Clouston Journal: Psychosom Med Date: 2021 Nov-Dec 01 Impact factor: 4.312